<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="836">
  <stage>Registered</stage>
  <submitdate>15/10/2005</submitdate>
  <approvaldate>16/11/2005</approvaldate>
  <actrnumber>ACTRN12605000745640</actrnumber>
  <trial_identification>
    <studytitle>Does metoclopramide improve quality of endoscopy in acute upper gastrointestinal bleeding?.</studytitle>
    <scientifictitle>Does metoclopramide improve quality of endoscopy in acute upper gastrointestinal bleeding?.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Upper Gastrointestinal Bleeding</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Normal oral and gastrointestinal development and function</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This study aims to investigate whether the administration of intravenous 10mg metoclopramide, 30-60minutes prior to endoscopy will improve the quality of endoscopic examination, will reduce the duration of endoscopic procedure and will decrease the need for repeat endoscopy</interventions>
    <comparator />
    <control>Placebo</control>
    <interventioncode>Diagnosis / Prognosis</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary outcome for this study is quality of endoscopic examination reported as:
a) % empty stomach using objective scores of 0 to 2.</outcome>
      <timepoint>Measured at time of endoscopic procedure by the gastroenterologist</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>The primary outcome for this study is quality of endoscopic examination to be reported as:
b) Ease of visibility of bleeding source, using a 7 point scale from no blood (7) to large amount of blood completely obscuring the view (1).</outcome>
      <timepoint>Measured at time of endoscopic procedure by the gastroenterologist</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The secondary outcomes will be based on analysis of results measured at time of endoscopic procedure and recorded on the case report form by the edoscopist after the procedure. This secondary outcome will be reported as: 1) % of patients with re-scope (due to problems with visualization) 2) Mean Duration of endoscopy (minutes).</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Upper GI bleeding defined as either fresh and bright red or coffee ground haematemesis, Admission within 12 hours of initial clinical signs of bleeding and Written informed consent from patient. </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Previous allergy to metoclopramide, use of Nasogastric tube or gastric lavage, Prior gastrectomy, Pregnancy or lactation, Unable to give informed consent for any reason, Parkinsons disease and other contraindication to use of metoclopramide, Severe renal impairment and Advanced liver disease .</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>treatment allocation will be concealed and they will be packaged in sequentially numbered sealed opaque envelopes</concealment>
    <sequence>Random numbers will be generated using Geigy scientific tables and these numbers will be used to assign the treatment allocation (using metoclopramide = 1 and placebo =2).</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>15/05/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>70</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Pharmacy department , Southerm Health.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Pharmacy department , Southerm Health</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Bunmi Adebayo</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bunmi Adebayo</name>
      <address>Pharmacy Department
Dandenong Hospital
Southern Health
Dandenong Melbourne VIC 3175</address>
      <phone>+61 3 95548303 or +61 3 95548302</phone>
      <fax>+61 3 97692073</fax>
      <email>bunmi_adebayo@hotmail.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Bunmi Adebayo</name>
      <address>Pharmacy Department
Dandenong Hospital
Southern Health
Dandenong Melbourne VIC 3175</address>
      <phone>+61 3 95548303 or +61 3 95548302</phone>
      <fax>+61 3 97692073</fax>
      <email>bunmi_adebayo@hotmail.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>